The blockade of CTLA-4 induces tumor rejection through various mechanisms, as illustrated in Figure 5A. Structural analyses were conducted using crystallography of Ipilimumab: The CTLA-4 complex demonstrated that ipilimumab exerts its effects by inhibiting interactions with B7, representing its primary mode of action [85]. The gene discussed is CTLA4; the disease is neoplasm.